CRYBB2 and cholangiocarcinoma: Futibatinib (TS-120), an FGFR inhibitor, led to an ORR of 37.7%, DCR of 82%, and median PFS of 7.2 months in advanced CCA patients who progressed after at least one prior line of therapy and with FGFR2 fusions/rearrangements (FOENIX-CCA2 trial) [21].